Aripiprazole
You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.
Aripiprazole Aurovitas contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics. The medicine is used to treat adults and adolescents aged 15 years and older who suffer from schizophrenia - a disease characterized by symptoms such as seeing, hearing, and feeling things that do not exist in reality, excessive suspiciousness, beliefs that contradict reality, chaotic speech and behavior, and emotional numbness. Patients with these symptoms may also experience sadness, fear, or tension, as well as feelings of guilt.
Aripiprazole is used to treat adults and adolescents aged 13 years and older whose disease is characterized by symptoms such as excitement, excessive energy, reduced need for sleep, very rapid speech, racing thoughts, and sometimes very severe irritability. In adults, the medicine also prevents the recurrence of the above symptoms in patients who have responded to aripiprazole treatment.
Before starting treatment with Aripiprazole Aurovitas, the patient should discuss the following with their doctor:
Suicidal thoughts and behaviors have been reported during treatment with aripiprazole. The patient should immediately inform their doctor if they experience suicidal thoughts or feelings of self-harm.
Before starting treatment with Aripiprazole Aurovitas, the patient should inform their doctor if they have:
If the patient experiences an increase in body weight, unusual movements, drowsiness that interferes with daily activities, difficulty swallowing, or signs of an allergic reaction, they should inform their doctor.
If an elderly patient has dementia (loss of memory and other mental abilities), the patient, their caregiver, or relative should inform the doctor if the patient has ever had a stroke or "mini-stroke".
The patient should immediately inform their doctor if they experience suicidal thoughts or feelings of self-harm. Suicidal thoughts and behaviors have been reported during treatment with aripiprazole.
The patient should immediately inform their doctor if they experience muscle stiffness or stiffness with high fever, sweating, changes in mental status, or very rapid or irregular heartbeat.
If the patient or their family or caregiver notices that the patient is starting to feel the urge or desire to behave in an unusual way, and cannot resist the impulse, drive, or temptation to engage in activities that may harm themselves or others, they should tell their doctor.
These phenomena are called impulse control disorders and may manifest as behaviors such as compulsive gambling, overeating, or excessive spending, excessive sexual desire, or an increase in the frequency and intensity of sexual thoughts or feelings.
The doctor may consider changing the dose or discontinuing the medicine.
Aripiprazole may cause drowsiness, decreased blood pressure when standing up, dizziness, and changes in mobility and balance, which can lead to falls. The patient should be cautious, especially if they are elderly or weakened.
This medicine should not be used in children and adolescents under the age of 13. It is not known if the use of the medicine is safe and effective in these patients.
The patient should tell their doctor or pharmacist about all medicines they are currently taking, or have recently taken, as well as any medicines they plan to take, including those that are available without a prescription.
Blood pressure-lowering medicines: Aripiprazole Aurovitas may enhance the effects of blood pressure-lowering medicines. If the patient is taking blood pressure-lowering medicines, they should inform their treating doctor.
Taking Aripiprazole Aurovitas with other medicines may require a change in the dose of Aripiprazole Aurovitas. It is especially important to inform the treating doctor about the use of:
Taking these medicines may increase the risk of undesirable effects or reduce the effectiveness of Aripiprazole Aurovitas. If the patient experiences any unusual symptoms while taking these medicines with Aripiprazole Aurovitas, they should tell their doctor.
Medicines that increase serotonin levels are usually used to treat diseases such as depression, generalized anxiety disorder, obsessive-compulsive disorder (OCD), and social phobia, as well as migraine and pain:
Taking these medicines may increase the risk of undesirable effects. If the patient experiences any unusual symptoms while taking these medicines with Aripiprazole Aurovitas, they should contact their doctor.
The medicine can be taken with or without food.
The patient should avoid drinking alcohol.
If the patient is pregnant, breastfeeding, or thinks they may be pregnant, they should consult their doctor before taking this medicine.
In newborns whose mothers took aripiprazole during the last trimester (last 3 months of pregnancy), the following symptoms may occur: tremors, muscle stiffness, and (or) weakness, drowsiness, agitation, breathing difficulties, and feeding difficulties. If the patient notices such symptoms in their child, they should contact their doctor.
If the patient is taking Aripiprazole Aurovitas, their doctor will discuss with them whether they should breastfeed, taking into account the benefits of treatment and the benefits of breastfeeding.
The patient should not take this medicine and breastfeed. They should discuss with their doctor the best methods of feeding their child if they are taking this medicine.
During treatment with this medicine, dizziness and vision disturbances may occur (see section 4).
The patient should take this into account when performing activities that require full attention, such as driving or operating machinery.
This medicine contains lactose monohydrate. If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking the medicine.
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that the medicine is considered "sodium-free".
Aripiprazole Aurovitas, 15 mg contains 1.5 mg of aspartame in each tablet.
Aripiprazole Aurovitas, 30 mg contains 3 mg of aspartame in each tablet.
Aspartame is a source of phenylalanine. It may be harmful to patients with phenylketonuria, a rare genetic disorder in which phenylalanine accumulates in the body due to its improper elimination.
Aripiprazole Aurovitas 15 mg contains 0.0054 mg of benzyl alcohol in each tablet.
Aripiprazole Aurovitas 30 mg contains 0.0108 mg of benzyl alcohol in each tablet.
Benzyl alcohol may cause allergic reactions. Patients with liver or kidney disease, pregnant or breastfeeding women should contact their doctor before taking the medicine, as a large amount of benzyl alcohol may accumulate in their body and cause undesirable effects (metabolic acidosis).
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. In case of doubts, the patient should consult their doctor or pharmacist.
Aripiprazole Aurovitas is available in 15 mg and 30 mg tablet forms. To take doses that cannot be achieved with this product, the patient should use an appropriate, available medicinal product containing aripiprazole. The patient should consult their treating doctor.
The recommended dose for adults is 15 mg once a day.However, the doctor may prescribe a lower or higher dose, but not more than 30 mg per day.
Treatment can be started with a low dose of aripiprazole in oral solution (liquid). The dose can be gradually increased to the recommended dose for adolescents, which is 10 mg once a day. However, the treating doctor may prescribe a lower or higher dose, up to a maximum of 30 mg per day.
If the patient feels that the effect of aripiprazole is too strong or too weak, they should consult their doctor or pharmacist.
Aripiprazole Aurovitas should be taken every day at the same time.It does not matter whether the tablet is taken with or without food. The tablet should be swallowed whole and washed down with water.
Even if the patient feels better, they should not change the dose or stop taking aripiprazole without first discussing it with their treating doctor.
In case of taking a higher dose of aripiprazole than prescribed by the doctor (or if someone else has taken some of the patient's Aripiprazole Aurovitas), the patient should immediately contact their treating doctor. If it is difficult to contact the doctor, the patient should go to the nearest hospital, taking the medicine packaging with them.
In patients who have taken too much aripiprazole, the following symptoms have occurred:
Other symptoms may include:
If the patient experiences any of the above symptoms, they should immediately contact their doctor or hospital.
If the patient misses a dose, they should take the missed dose as soon as they remember. They should not take two doses in one day.
The patient should not stop treatment if they feel better.
It is very important to take Aripiprazole Aurovitas exactly as prescribed by the doctor and for the duration prescribed by the doctor.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
The following side effects have been reported after the medicine was placed on the market, but their frequency is not known:
In elderly patients with dementia taking aripiprazole, more cases of death have been reported. Additionally, cases of stroke or "mini-stroke" have been noted.
In adolescents aged 13 years and older, side effects occurred with a similar frequency and type as in adults, with the exception of drowsiness, uncontrolled body movements, or sudden movements of the limbs, restlessness, and fatigue, which occurred very frequently (more frequently than in 1 in 10 patients), as well as abdominal pain, dry mouth, rapid heartbeat, weight gain, increased appetite, tremors, uncontrolled movements of the limbs, and dizziness, especially when standing up, which occurred frequently (more frequently than in 1 in 100 patients).
If the patient experiences any side effects, including those not mentioned in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Adverse Reaction Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49-21-301, fax: +48 22 49-21-309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects helps to gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
There are no special precautions for storing the medicine.
The medicine should not be used after the expiry date stated on the packaging and blister pack after: "Expiry date (EXP)". The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of the medicine is aripiprazole.
Aripiprazole Aurovitas, 15 mg: each tablet contains 15 mg of aripiprazole.
Aripiprazole Aurovitas, 30 mg: each tablet contains 30 mg of aripiprazole.
The other ingredients are: lactose monohydrate, microcrystalline cellulose (E 460), croscarmellose sodium, colloidal anhydrous silica, aspartame (E 951), magnesium stearate (E 470b), vanilla flavor (including maltodextrin, gum arabic (E414), propylene glycol, benzyl alcohol, and vanilla flavor), yellow iron oxide (E 172) (Aripiprazole Aurovitas, 15 mg) or red iron oxide (E 172) (Aripiprazole Aurovitas, 30 mg).
Aripiprazole Aurovitas, 15 mg: yellow, round, flat, and smooth tablets on both sides.
Aripiprazole Aurovitas, 30 mg: pink, round, flat, and smooth tablets on both sides.
Aripiprazole Aurovitas is available in blisters of OPA/Aluminum/PVC/Aluminum foil, packaged in cardboard boxes containing 28 and 56 tablets.
Not all pack sizes may be marketed.
Aurovitas Pharma Polska Sp. z o.o.
ul. Sokratesa 13D, lokal 27
01-909 Warsaw
Poland
tel.: +48 22 311 20 00
Rontis Hellas Medical and Pharmaceutical Products S.A.
P.O. Box 3012 Larisa Industrial Area
41004 Larisa
Greece
Genepharm S.A.
18th km Marathonos Avenue,
15351 Pallini Attiki
Greece
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.